Evotec maps path to profitability

Germany's Evotec says that research alliances with top biopharma companies will push up sales by 20 percent for each of the next three years. And that would put the company on a path to become "sustainably" profitable in 2012. Evotec hasn't been profitable since it went public in 1999. Report